Development and Validation of UV Spectrophotometric method for the estimation of Sofosbuvir and Ledipasvir in combined Pharmaceutical dosage forms

Two simple spectrophotometric methods have been developed for simultaneous estimation of Sofosbuvir and Ledipasvir in combined dosage forms has been developed. Method-I simultaneous equation method involves the measurement of absorbances at two wavelengths 237 nm (λmax of Sofosbuvir) and 247 nm (λ max of Ledipasvir) in diluents of water and methanol in the ratio of 8:2 (v/v).Method-II involvesderivative spectrophotometry method for simultaneous estimation of Sofosbuvir and Ledipasvir. In this method, the absorbance was measured at 237 nm for Sofosbuvir and 247 nm for Ledipasvir. Linearity was observed in range of 20-120 μg/ml and 4.5-27 μg/ml for Sofosbuvir and Ledipasvir respectively. Accuracy of method was found between 98 to 102%. The precision (intra‐day, inter‐day) of method was found within limits. Both method were found to be rapid, specific, precise and accurate and can be successfully applied for the routine analysis of Sofosbuvir and Ledipasvir in combined dosage form.

[1]  A. Praveenkumar,et al.  METHOD DEVELOPMENT AND VALIDATION OF ULTRAVIOLET-VISIBLE SPECTROSCOPIC METHOD FOR THE ESTIMATION OF HEPATITIS-C DRUGS - DACLATASVIR AND SOFOSBUVIR IN ACTIVE PHARMACEUTICAL INGREDIENT FORM , 2016 .

[2]  Bakht Zaman,et al.  RP-HPLC Method for Simultaneous Determination of Sofosbuvir and Ledipasvir in Tablet Dosage Form and Its Application to In Vitro Dissolution Studies , 2016, Chromatographia.

[3]  Bryony Simmons,et al.  Rapid reductions in prices for generic sofosbuvir and daclatasvir to treat hepatitis C , 2016, Journal of virus eradication.

[4]  Yongping Chen,et al.  Simultaneous determination of ledipasvir, sofosbuvir and its metabolite in rat plasma by UPLC-MS/MS and its application to a pharmacokinetic study. , 2016, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[5]  P. Marcellin,et al.  Treatment with ledipasvir and sofosbuvir improves patient‐reported outcomes: Results from the ION‐1, ‐2, and ‐3 clinical trials , 2015, Hepatology.

[6]  Brad J. Wood,et al.  Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection. , 2015, JAMA.

[7]  J. Rockstroh,et al.  Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study , 2015, The Lancet.

[8]  M. Nguyen,et al.  Fixed-dose combination of sofosbuvir and ledipasvir for the treatment of chronic hepatitis C genotype 1 , 2015, Expert opinion on pharmacotherapy.

[9]  L. Chan,et al.  Synthesis and evaluation of NS5A inhibitors containing diverse heteroaromatic cores. , 2015, Bioorganic & medicinal chemistry letters.

[10]  Lawrence Carey.  What is the role of sofosbuvir in treating hepatitis C infection? , 2015, JAAPA : official journal of the American Academy of Physician Assistants.

[11]  E. Yoshida,et al.  Hepatitis C drugs: the end of the pegylated interferon era and the emergence of all-oral interferon-free antiviral regimens: a concise review. , 2014, Canadian journal of gastroenterology & hepatology.

[12]  Stefan Zeuzem,et al.  Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. , 2014, The New England journal of medicine.

[13]  Amy D. Fung,et al.  Efficiency of Incorporation and Chain Termination Determines the Inhibition Potency of 2′-Modified Nucleotide Analogs against Hepatitis C Virus Polymerase , 2014, Antimicrobial Agents and Chemotherapy.

[14]  T. Asselah.  Sofosbuvir for the treatment of hepatitis C virus , 2014, Expert opinion on pharmacotherapy.

[15]  G. Venkateshwarlu,et al.  Spectrophotometric Determination Of Drugs Using N-Bromosuccinimide And Rhodamine-B Dye , 2013 .